Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cipher Pharmaceuticals has submitted a revised new drug application to the FDA for CIP-Tramadol ER, its extended-release formulation of tramadol.
Subscribe to our email newsletter
The company’s revised new drug application (NDA) includes data from additional pharmacokinetic studies conducted by the company comparing CIP-Tramadol ER to Ultram ER. Subject to FDA acceptance for filing, the company expects the review to be completed by October 2008.
After considering feedback from the FDA appeal process and the results of the additional statistical sensitivity analysis of existing data suggested by the FDA, the company and its advisors concluded that submitting the revised NDA provided the most expeditious path to final regulatory approval.